Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: A single-center retrospective study

Rheumatology International, Journal Year: 2024, Volume and Issue: 44(7), P. 1283 - 1294

Published: March 28, 2024

Abstract Background Lupus nephritis (LN) manifests systemic lupus erythematosus (SLE) and is characterized by various clinical laboratory features. This study aimed to comprehensively evaluate the characteristics of LN patients according time diagnosis: early-onset (LN diagnosed within one year from SLE diagnosis) vs. delayed-onset more than after diagnosis). Methods We conducted a retrospective analysis medical records all treated at University Hospital in Kraków, Poland, 2012 2022. collected data on demographic, clinical, characteristics, including histological findings, treatment modalities, disease outcomes. Statistical analyses were performed identify factors impacting development prognosis. Results Among 331 patients, was 207 (62.54%) documented 122 cases (36.86%). In 2 (0.6%) cases, first kidney manifestation course unknown. Delayed-onset had higher female-to-male ratio younger age diagnosis. group associated with severe manifestations. turn, studied subgroups did not differ internist comorbidities, histopathology, family history regarding autoimmune diseases. exhibited frequency anti-dsDNA, anti-Smith, anti-Ro, anti-RNP, anti-cardiolipin IgG autoantibodies. During 14-year follow-up period, 16 died. Mortality rate causes death comparable both analyzed subgroups. Conclusions More manifestations prompt strict monitoring non-LN diagnose treat involvement early. Also, recognizing autoantibodies such as anti-dsDNA or anti-Smith underscores potential value autoantibody profiling diagnostic prognostic tool.

Language: Английский

---

Delayed onset lupus nephritis in the course of systemic lupus erythematosus: Relation to disease activity and therapeutic response

The Egyptian Rheumatologist, Journal Year: 2025, Volume and Issue: 47(2), P. 65 - 69

Published: Jan. 17, 2025

Language: Английский

---

Testosterone deficiency and chronic kidney disease

Journal of Clinical & Translational Endocrinology, Journal Year: 2024, Volume and Issue: 37, P. 100365 - 100365

Published: Aug. 14, 2024

Testosterone's biological functions are extensive, influencing reproductive and systemic health. It plays a vital role in sexual functions, muscle protein synthesis, bone metabolism, fat distribution, cardiovascular The hormone also affects mood, cognitive function, erythropoiesis, underscoring its importance both physical mental Testosterone deficiency, or male hypogonadism, is increasingly recognized as significant health issue affecting various bodily systems, the context of chronic kidney disease (CKD). Recent research indicates complex interplay between testosterone levels renal health, suggesting that hypogonadism may impact be impacted by CKD. latter characterized gradual loss millions globally often associated with diabetes mellitus, arterial hypertension, autoimmune diseases. Men CKD frequently experience lower levels, which can exacerbate wasting, reduce quality life, increase risk. Overall, low patients increased morbidity mortality. Several mechanisms explain relationship deficiency. uremic environment disrupts hypothalamic-pituitary-gonadal axis, impairing production. Nutritional deficiencies inflammation common further suppress gonadal function. consequences profound, studies replacement therapy (TRT) might improve clinical outcomes, though long-term effects causal relationships remain under investigation. potential benefits TRT significant. enhance mass strength, address anemia stimulating density, possibly offer improving body composition insulin sensitivity. General symptoms such deteriorated psychological, wellbeing, improved TRT. However, these must weighed against risks. fluid retention, existing heart failure, particularly pre-existing comorbidities. Additionally, concerns about progression via several affected pathways involving tubular integrity exist, highlighting need for careful patient selection monitoring. Understanding this crucial developing comprehensive treatment strategies endocrine dysfunctions, integrated care, means good collaboration subspecialists like nephrologists, endocrinologists, urologists primary care providers, aiming to outcomes life while mitigating adverse effects.

Language: Английский

---

Clinico-serological associations of urinary activated leukocyte cell adhesion molecule in systemic lupus erythematosus and lupus nephritis

Clinical Rheumatology, Journal Year: 2024, Volume and Issue: 43(3), P. 1015 - 1021

Published: Jan. 31, 2024

Lupus nephritis (LN) is one of the major complications associated with Systemic Erythematosus (SLE). Activated leukocyte cell adhesion molecule (ALCAM or CD166) a promising urine biomarker that binds to CD6, receptor found on lymphocytes. This binding results in T-cell activation, proliferation, and recruitment, which causes tissue inflammation may explain pathophysiology LN.

Language: Английский

---

Characteristics of systemic lupus erythematosus in patients of Asian ethnicity

Modern Rheumatology Journal, Journal Year: 2025, Volume and Issue: 19(1), P. 76 - 82

Published: Feb. 15, 2025

Systemic lupus erythematosus (SLE) is characterized by an unpredictable and unfavorable course. The ethnicity of the patient has a significant impact on course outcome disease. SLE more severe in African Americans Asians than white Europeans. This review examines epidemiological data, characteristics clinical manifestations Asians.

Language: Английский

---

Therapeutic progress in the targeting of B cells in lupus nephritis: pathogenesis to clinical research

International Urology and Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

---

Urinary MCP-1 and VCAM-1 as non-invasive biomarkers for the diagnosis and activity assessment of lupus nephritis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0323334 - e0323334

Published: May 19, 2025

Introduction Accurate diagnosis of lupus nephritis (LN) and effective assessment its disease activity are essential for optimal management. This study aimed to evaluate the potential novel urinary biomarkers, MCP-1 VCAM-1, in diagnosing assessing LN activity, comparing their efficacy traditional proposing a new standard clinical application. Methods A total 55 patients who met 1997 ACR diagnostic criteria systemic erythematosus (SLE) 34 healthy controls (HCs) were included this study. The categorized into two groups based on SLE indices (SLEDAI): inactive (NALN) group (SLEDAI 0–4, n = 32) active (ALN) (renal SLEDAI ≥ 4, 22). Additionally, further classified mild 5–9), moderate 10–14), severe > 14) subgroups. All underwent testing (uMCP-1), VCAM-1 (uVCAM-1), α1-microglobulin (u-α1MG), β2-microglobulin (u-β2MG), IgG (u-IgG), albumin (u-ALB), as well percutaneous renal biopsy. Results levels (uMCP-1 uVCAM-1) significantly elevated compared HCs (uMCP-1: P < 0.001; uVCAM-1: 0.01). Receiver operating characteristic (ROC) curve analysis revealed that uMCP-1 uVCAM-1 surpassed biomarkers AUC 0.79, 0.77, 0.001). Multivariate logistic regression demonstrated significant association between occurrence ( Furthermore, these exhibited stronger correlations with scores than (P Notably, ALN had higher those NALN 0.01; Conclusion production is closely associated onset progression (ISN/RPS: Class I - IV). These may serve valuable references prediction aid activity.

Language: Английский

---

The insertion/deletion gene polymorphism of angiotensin-converting enzyme and its serum level in lupus nephritis among Egyptians

Gene Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102264 - 102264

Published: May 1, 2025

Language: Английский

---

Anti-Smith Antibodies as a Predictive Factor for Developing Lupus Nephritis in Systemic Lupus Erythematosus Patients: A Systematic Review

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 6, 2024

Lupus nephritis (LN) is the most frequent and lethal complication of systemic lupus erythematosus (SLE), often presenting with subtle or no initial symptoms. Therefore, it crucial to identify SLE patients who are at risk developing LN ensure they receive timely intervention. Significant scientific efforts have been made various genes antibodies that could increase LN. Our objective review role anti-Smith in this disease evaluate their potential as a predictive marker for This was done accordance Preferred Reporting Items Systematic Reviews Meta-Analysis (PRISMA) guidelines. We searched different study types from 2019 onwards per our inclusion exclusion criteria, look significance antibodies. The following databases were used: PubMed, PMC, Google Scholar, Science Direct, Scopus. Twenty-two studies checked eligibility, which 17 passed, based on commonly used quality assessment tool each corresponding studies. results indicated highly specific part its classification criteria. In addition, we observed positive titers correlate activity. presence influenced by ethnicity being common among Black patients. However, data regarding effectiveness not fully established. A more sensitive investigation larger cohorts diverse ethnic populations provide definitive answer LN, highlighting need additional research.

Language: Английский

---

Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report

Journal of Translational Autoimmunity, Journal Year: 2023, Volume and Issue: 7, P. 100223 - 100223

Published: Dec. 1, 2023

Bacterial recombinant cysteine protease Ides (imlifidase, Idefirix®, Hansa Biopharma) is used to prevent humoral transplant rejection in highly HLA-sensitized recipients, and control IgG-mediated autoimmune diseases. We report the case of a 51 years old woman suffering from lupus nephritis with end stage kidney disease, grafted for second time pre-treated imlifidase. The patient was HLA-hypersensitized (calculated Panel Reactive Antibodies [Abs], cPRA>99 %) has three preformed Donor Specific (DSA). Circulating immunoglobulins were monitored at initiation (0, 6, 36, 72 96 h), Ab recovery one two months following imlifidase injection. From baseline, higher depletion reported after 36h total IgG (-75 subclasses (-87 % IgG1, IgG2 IgG3, -78 IgG4), while no significant impact on IgA IgM observed. Anti-SSA 60 kDa anti-SSB auto-Abs quickly decreased injection (-96 both 36 h) as well post-vaccinal specific (-95 tetanus toxoid, -97 pneumococcus -91

Language: Английский

---